BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Alzheimers Society of Toronto - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://alz.to
X-WR-CALDESC:Events for Alzheimers Society of Toronto
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20260108T100000
DTEND;TZID=America/Toronto:20260108T110000
DTSTAMP:20260428T175206
CREATED:20251126T201912Z
LAST-MODIFIED:20251211T190835Z
UID:10003579-1767866400-1767870000@alz.to
SUMMARY:UHN Caregiver Talks: The latest news in the treatment of Alzheimer's disease
DESCRIPTION:Description: \nJoin us for an update on new Alzheimer’s treatments and how they may impact everyday life for individuals and families affected by the disease. We’ll cover what’s new\, what’s promising\, and what these developments mean for care today and in the future. \nPresented in partnership with the University Health Network Krembil Memory Clinic and the Alzheimer Society of Toronto. \n  \nAbout the Presenter \nDr. Tartaglia is a cognitive neurologist at the UHN Memory Clinic where she sees patients with neurodegenerative diseases and those with concussions who have persisting symptoms. She is a scientist and Associate Professor at the University of Toronto. She holds the Marion and Gerald Soloway Chair in Brain Injury and Concussion Research. She uses a multi-modal approach that combines imaging and biofluid biomarkers to better diagnose and understand the pathological substrates that cause cognitive\, behavioral and motoric dysfunction. The goal of her research program is to develop biomarkers for early detection of disease to bring precision medicine and targeted\, early treatments to her patients. \n 
URL:https://alz.to/calendar/uhn-caregiver-talks-the-latest-news-in-the-treatment-of-alzheimers-disease/
CATEGORIES:Webinars
ATTACH;FMTTYPE=image/jpeg:https://alz.to/wp-content/uploads/2025/03/AdobeStock_1269275805-scaled.jpeg
ORGANIZER;CN="Alzheimer Society of Toronto":MAILTO:info@alz.to
LOCATION:https://alz.to/calendar/uhn-caregiver-talks-the-latest-news-in-the-treatment-of-alzheimers-disease/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20260129T120000
DTEND;TZID=America/Toronto:20260129T130000
DTSTAMP:20260428T175206
CREATED:20260108T143359Z
LAST-MODIFIED:20260113T214050Z
UID:10003663-1769688000-1769691600@alz.to
SUMMARY:Disease-Modifying Therapies for Alzheimer's Disease in Canada: What They Mean for People Living with Dementia and their Families
DESCRIPTION:To mark Alzheimer’s Awareness Month\, the Alzheimer Society of Toronto and the Toronto Dementia Research Alliance (TDRA) invite you to a virtual panel focused on new disease-modifying therapies (DMTs) for Alzheimer’s disease in Canada\, including recently approved treatments such as lecanemab. \nSummary: \nMost current treatments for Alzheimer’s disease help manage symptoms but do not slow the disease itself. Disease-modifying therapies are different. They aim to slow the disease by targeting changes in the brain\, such as the buildup of amyloid. \nThese treatments bring new hope\, but they also raise important questions. Who may be eligible? What tests are needed? How will people access these treatments in Canada? What benefits and risks should families understand? \nDuring this panel\, experts and people with lived experience will discuss: \n– What disease-modifying therapies are and how they work \n– Who these treatments may be for and how eligibility is decided \n– What testing and monitoring are needed \n– How access and funding may work across Canada \n– What slowing disease progression may look like in daily life \nThis event will be presented in plain language and will include time for audience questions. \nPresented in partnership with the Toronto Dementia Research Alliance and the Alzheimer Society of Toronto. \n  \nAbout the Presenters \nDr. Carmela Tartaglia \nDr. Carmela Tartaglia is a Cognitive Neurologist who cares for people with neurodegenerative diseases. She is Co-Director and Medical Lead of the Toronto Western Hospital Memory Clinic and a Professor of Medicine at the University of Toronto. \nShe is also the Executive Director of the Toronto Dementia Research Alliance (TDRA). Dr. Tartaglia has helped lead projects such as the Toronto Cognitive Assessment (TorCA) and research using brain imaging and biomarkers to support earlier and more accurate diagnosis. Her work focuses on improving access to timely and targeted care for people living with cognitive disorders. \nChad Mitchell \nChad Mitchell is a health policy expert and Senior Associate at Global Public Affairs. He has more than 20 years of experience working in Canada’s health system on drug policy\, health technology review\, and health system planning. \nHe has held senior leadership roles with the pan-Canadian Pharmaceutical Alliance and the Canadian Agency for Drugs and Technologies in Health (CADTH). Chad works with governments and health organizations to support fair access to new treatments across Canada. \nCara Sullivan \nCara is a retired high school English teacher and a member of TDRA’s Lived Experience Advisory Partners Council. She became engaged in Alzheimer’s research in 2016 after supporting a family member as part of a caregiving team\, with support from the Alzheimer Society of Toronto and the Alzheimer Society of Grey-Bruce. Cara has participated in several clinical trials with the Toronto Memory Program and CAMH and has a strong interest in risk reduction and brain health. She is currently the study partner for a family member who recently completed two years in the AHEAD Alzheimer’s prevention study at Sunnybrook Hospital. \nPaul Lea \nPaul is a member of TDRA’s Lived Experience Advisory Partners (LEAP) Council. He experienced a major stroke in 2008 and was diagnosed with vascular dementia in 2009. After connecting with the Alzheimer Society of Toronto in 2015\, Paul became an active advocate and spokesperson\, raising awareness about stigma\, prevention\, and the need for better supports for people living with dementia. He continues to challenge himself cognitively and has developed effective strategies to adapt to the changes associated with vascular dementia. \n 
URL:https://alz.to/calendar/disease-modifying-therapies-for-alzheimers-disease-in-canada-what-they-mean-for-people-living-with-dementia-and-their-families/
CATEGORIES:Learn,Webinars
ATTACH;FMTTYPE=image/png:https://alz.to/wp-content/uploads/2026/01/Webinar-photo.png
ORGANIZER;CN="Alzheimer Society of Toronto":MAILTO:info@alz.to
LOCATION:https://alz.to/calendar/disease-modifying-therapies-for-alzheimers-disease-in-canada-what-they-mean-for-people-living-with-dementia-and-their-families/
END:VEVENT
END:VCALENDAR